



Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study

Diabetes Care 2020;43:e174–e177 | <https://doi.org/10.2337/dc20-1217>

Matthieu Wargny,¹ Pierre Gourdy,² Lisa Ludwig,³ Dominique Seret-Bégué,⁴ Olivier Bourron,⁵ Patrice Darmon,⁶ Coralie Amadou,⁷ Matthieu Pichelin,⁸ Louis Potier,⁹ Charles Thivolet,¹⁰ Jean-François Gautier,¹¹ Samy Hadjadj,⁸ and Bertrand Cariou,⁸ for the CORONADO investigators*

Since the start of the coronavirus disease 2019 (COVID-19) pandemic, patients with diabetes were rapidly recognized as a high-risk population for severe disease. Indeed, a high prevalence of diabetes among patients with COVID-19 who required hospitalization has been consistently reported, reaching 33.8% in 5,700 people hospitalized for COVID-19 in the New York City area (1). In addition, diabetes was associated with more than a doubled risk of intensive care unit (ICU) admission and more than a tripled risk of death (2). However, precise data regarding the type of diabetes are scarce. We report here the clinical characteristics and early prognosis of patients with type 1 diabetes (T1D) hospitalized for COVID-19 in the nationwide multicenter observational CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study (3).

The aim of the CORONADO study was to describe the phenotypic characteristics and prognosis of patients with diabetes admitted with COVID-19 between 10 March and 10 April 2020 in 68 French hospitals. The protocol (ClinicalTrials.gov reg. no. NCT04324736) obtained all regulatory approvals as recently described (3). Inclusion criteria were 1) hospitalization for biologically and/or clinically/radiologically attested COVID-19 and 2) personal history of diabetes or newly diagnosed diabetes on admission. The composite primary end point combined tracheal intubation for mechanical ventilation and/or death on day 7 (D7). Secondary outcomes included death, tracheal intubation, and discharge on D7. Classification of diabetes was recorded in the electronic case report form as noted in the medical file by the physician in charge of the patient. In the present subanalysis,

patients in whom diabetes was diagnosed on admission were excluded since the etiological diagnosis had not been formally established. All cases noted as T1D were carefully reviewed by local investigators and the steering committee based on clinical and biological information. As an additional control, we applied the ENTRED (Échantillon National Témoin Représentatif des Personnes Diabétiques) study algorithm (4) and systematically reviewed diabetes classification of all individuals diagnosed under 45 years of age and treated with insulin within 2 years of diagnosis.

Among the patients with previously established diabetes and with data availability for the primary outcome ($n = 2,608$), 56 had T1D (2.1%). Their main clinical characteristics are shown in Table 1, with male predominance (55.4%), mean (\pm SD) age of 56.0 (\pm 16.4)

¹Clinique des Données, CHU Nantes, CIC Inserm 1413, Nantes, France

²CHU de Toulouse and UMR1048/I2MC, Université de Toulouse, Toulouse, France

³Hôpital Brabois, CHRU Nancy, Université de Lorraine, Nancy, France

⁴Centre Hospitalier de Gonesse, Gonesse, France

⁵Sorbonne Université; Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris; INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris 06; Institute of Cardiometabolism and Nutrition, Paris, France

⁶Département d'Endocrinologie et de Diabétologie, Hôpital de la Conception, Assistance Publique Hôpitaux de Marseille, Marseille, France

⁷Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, Université Paris-Saclay, France

⁸L'institut du thorax, CHU Nantes, CNRS, Inserm, Université de Nantes, Nantes, France

⁹Département de Diabétologie, Nutrition et Endocrinologie, CHU Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France

¹⁰Centre du Diabète DIAB-eCARE, Hospices Civils de Lyon et laboratoire CarMeN, INSERM, INRA, INSA, Université Claude Bernard Lyon 1, Lyon, France

¹¹Département Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France

Corresponding author: Bertrand Cariou, bertrand.cariou@univ-nantes.fr

Received 21 May 2020 and accepted 24 July 2020

Clinical trial reg. no. NCT04324736, clinicaltrials.gov

This article contains supplementary material online at <https://doi.org/10.2337/figshare.12728246>.

*A complete list of the CORONADO trial investigators is provided in the supplementary material online.

This article is part of a special article collection available at <https://care.diabetesjournals.org/collection/diabetes-and-COVID19>.

© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.

Table 1—Clinical characteristics of CORONADO participants with T1D according to the primary outcome (tracheal intubation and/or death on D7)
Primary outcome on day 7

Clinical features	Available data (N)	All	No (N = 43)		Yes (N = 13)		No adjustment		Adjusted on age	
			No (N = 43)	Yes (N = 13)	OR (95% CI)	P value	OR (95% CI)	P value		
Sex (female/male)	56	25/56 (44.6)	20/43 (46.5)	5/13 (38.5)	0.72 (0.20–2.55)	0.6097	0.73 (0.19–2.78)	0.6415		
Age (years)	56	56.0 ± 16.4	53.2 ± 15.5	65.3 ± 16.3	1.05 (1.01–1.10)	0.0260	NA	—		
Age (categories)										
<55 years		25/56 (44.6)	22/43 (51.2)	3/13 (23.1)	1 (ref.)	0.3004	NA	—		
55–74 years		21/56 (37.5)	16/43 (37.2)	5/13 (38.5)	2.29 (0.48–11.0)	0.3004	NA	—		
≥75 years		10/56 (17.9)	5/43 (11.6)	5/13 (38.5)	7.33 (1.30–41.4)	0.0240	NA	—		
Diabetes duration (years)	50	26.0 [15.0; 39.5]	25.0 [15.0; 34.5]	40.0 [20.5; 52.0]	1.22 (0.57–2.62)	0.6071	0.78 (0.34–1.76)	0.5457		
BMI (kg/m ²)	52	25.8 [22.5; 29.8]	25.1 [22.3; 29.5]	26.3 [23.5; 32.0]	1.45 (0.75–2.80)	0.2706	1.91 (0.86–4.23)	0.1102		
Obesity (yes)	52	13/52 (25.0)	9/40 (22.5)	4/12 (33.3)	1.72 (0.42–7.06)	0.4502	2.34 (0.50–11.0)	0.2805		
HbA _{1c} (mmol/mol)	41	68.3 [59.6; 80.3]	73.2 [62.3; 82.0]	65.0 [53.0; 68.3]	0.52 (0.23–1.18)	0.1174	0.48 (0.19–1.21)	0.1188		
HbA _{1c} (%)	41	8.4 [7.6; 9.5]	8.8 [7.9; 9.7]	8.1 [7.0; 8.4]	0.50 (0.21–1.18)	0.1126	0.46 (0.17–1.21)	0.1149		
Long-term diabetes complications										
Microvascular complications	51	25/51 (49.0)	18/38 (47.4)	7/13 (53.8)	1.30 (0.37–4.58)	0.6871	1.01 (0.26–3.89)	0.9942		
Severe diabetic retinopathy	52	19/52 (36.5)	14/40 (35.0)	5/12 (41.7)	1.33 (0.35–4.96)	0.6745	1.19 (0.30–4.76)	0.8065		
Diabetic kidney disease	49	14/49 (28.6)	10/36 (27.8)	4/13 (30.8)	1.16 (0.29–4.62)	0.8379	0.71 (0.15–3.44)	0.6712		
Macrovascular complications	52	17/52 (32.7)	13/39 (33.3)	4/13 (30.8)	0.89 (0.23–3.44)	0.8645	0.47 (0.10–2.07)	0.3156		
Macrovascular heart disease (ACS/CAR)	54	13/54 (24.1)	9/41 (22.0)	4/13 (30.8)	1.58 (0.39–6.35)	0.5190	0.90 (0.20–4.07)	0.8901		
Cerebrovascular disease (stroke or TIA)	55	5/55 (9.1)	3/42 (7.1)	2/13 (15.4)	2.36 (0.35–16.0)	0.3775	1.13 (0.15–8.44)	0.9028		
Comorbidities										
Hypertension	54	26/54 (48.1)	16/41 (39.0)	10/13 (76.9)	5.21 (1.24–21.9)	0.0242	3.33 (0.71–15.5)	0.1259		
Dyslipidemia	55	27/55 (49.1)	19/42 (45.2)	8/13 (61.5)	1.94 (0.54–6.91)	0.3083	0.99 (0.24–4.18)	0.9945		
Tobacco use (former or current vs. never)	48	18/48 (37.5)	13/37 (35.1)	5/11 (45.5)	1.54 (0.39–6.03)	0.5363	0.91 (0.20–4.09)	0.9035		
Active cancer	56	6/56 (10.7)	3/43 (7.0)	3/13 (23.1)	4.00 (0.70–22.9)	0.1192	2.24 (0.36–14.0)	0.3876		
COPD	54	2/54 (3.7)	1/42 (2.4)	1/12 (8.3)	3.73 (0.22–64.5)	0.3657	3.93 (0.18–84.6)	0.3824		
Treated OSA	52	6/52 (11.5)	4/40 (10.0)	2/12 (16.7)	1.80 (0.29–11.3)	0.5304	1.59 (0.24–10.5)	0.6323		
Routine treatment before admission										
Metformin	56	7/56 (12.5)	4/43 (9.3)	3/13 (23.1)	2.92 (0.56–15.2)	0.2024	2.93 (0.51–16.7)	0.2270		
Insulin pump (yes/no)	53	6/53 (11.3)	4/40 (10.0)	2/13 (15.4)	1.64 (0.26–10.2)	0.5972	3.15 (0.41–24.3)	0.2706		
Insulin (daily dose)	45	41 [25; 60]	41 [26; 55]	42 [21; 77]	1.29 (0.63–2.66)	0.4877	1.61 (0.70–3.69)	0.2583		
ARBs and/or ACE inhibitors	56	22/56 (39.3)	15/43 (34.9)	7/13 (53.8)	2.18 (0.62–7.66)	0.2252	1.69 (0.44–6.39)	0.4426		
Statins	56	23/56 (41.1)	16/43 (37.2)	7/13 (53.8)	1.97 (0.56–6.90)	0.2895	1.28 (0.33–4.91)	0.7189		

Data are presented as numbers (%), mean ± SD, or, if not normally distributed, median [25th; 75th percentile]. P values are calculated using Wald test in logistic regression model before/after adjustment on age, BMI, diabetes duration, HbA_{1c}, and insulin (daily dose) were natural-log transformed before OR calculation, and the OR are calculated for an increase of 1 SD. ACS, acute coronary syndrome; ARB, angiotensin 2 receptor blocker; CAR, coronary artery revascularization; COPD, chronic obstructive pulmonary disease; NA, not applicable; OSA, obstructive sleep apnea; TIA, transient ischemic attack; HbA_{1c}, corresponds to the HbA_{1c} value determined in the 6 months prior to or in the first 7 days following hospital admission. Microvascular complications were defined as severe diabetic retinopathy (proliferative retinopathy and/or laser photocoagulation and/or clinically significant macular edema requiring laser and/or intravitreal injections) and/or diabetic kidney disease (proteinuria [albumin excretion rate ≥300 mg/24 h, urinary albumin-to-creatinine ratio ≥300 mg/g; urinary albumin-to-creatinine ratio >30 mg/mmol creatinine; proteinuria ≥500 mg/24 h] and/or estimated glomerular filtration rate ≤60 mL/min/1.73 m², using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) and/or history of diabetic foot ulcer. Macrovascular complications were defined as ischemic heart disease (ACS and/or CAR) and/or cerebrovascular disease (stroke or TIA) and/or peripheral artery disease (amputation owing to ischemic disease and/or lower-limb artery revascularization).

Table 2—Clinical outcomes on D7 in patients with T1D and patients with T2D, according to age strata

	T1D (n = 56)			T2D (n = 2,373)		
	Primary outcome	Tracheal intubation	Death	Primary outcome	Tracheal intubation	Death
All	13/56 (23.2)	11/56 (19.6)	3/56 (5.4)	657/2,373 (27.7)	436/2,373 (18.4)	251/2,373 (10.6)
Age subgroups						
<55 years	3/25 (12.0)	3/25 (12.0)	0/25 (0)	78/256 (30.5)	76/256 (29.7)	5/256 (2.0)
55–74 years	5/21 (23.8)	5/21 (23.8)	1/21 (4.8)	333/1,168 (28.5)	290/1,168 (24.8)	62/1,168 (5.3)
≥75 years	5/10 (50.0)	3/10 (30.0)	2/10 (20.0)	246/949 (25.9)	70/949 (7.4)	184/949 (19.4)

Data are number of events/total number of participants (%).

years, and median (25th; 75th percentile) BMI of 25.8 (22.5; 29.9) kg/m². In patients with T1D, 13 (23.2%) met the primary outcome, 11 (19.6%) required tracheal intubation for mechanical ventilation, 3 (5.4%) died, and 9 (16.1%) were discharged on D7, compared with 657/2,373 (27.7%), 436/2,373 (18.4%), 251/2,373 (10.6%), and 483/2,363 (20.4%) in patients with T2D, respectively. As shown in Table 1, patients with T1D who met the primary outcome were older (65.3 vs. 53.2 years, $P = 0.026$) and more frequently hypertensive (odds ratio [OR] 5.21 [95% CI 1.24–21.9], $P = 0.024$) than the others. Hypertension was no longer associated with the primary outcome after adjustment for age (OR 3.33 [95% CI 0.71–15.5], $P = 0.13$). In order to further determine the impact of age on COVID-19 severity in people with T1D and type 2 diabetes (T2D), we analyzed the occurrence of major clinical outcomes on D7 by age strata (<55, 55–74, and ≥75 years) (Table 2). As expected, patients with T1D were significantly younger than those with T2D (56.0 ± 16.4 vs. 70.5 ± 12.5 years, $P < 0.0001$). In patients <55 years of age, those with T1D met the primary outcome three times less than those with T2D, without such a difference in those ≥75 years.

For the first time, we show a prevalence of T1D among patients with diabetes hospitalized for COVID-19 (2.1%) that is lower than expected in the general population. Indeed, a previous epidemiological study in the general population reported that T1D accounts for 5.6% of people with diabetes in France (5). Notably, such a low prevalence of T1D among patients admitted with COVID-19 is primarily observed in people <55 years (7.8% in CORONADO vs. 23.2% in the French general population [5]). In addition, early severity of COVID-19 in patients with T1D was mainly influenced by age, with no deaths occurring in

patients <65 years. Hypertension was associated with the severity of COVID-19 prognosis, but this association was partly driven by age. Finally, neither long-term glucose control assessed by HbA_{1c} nor history of micro- or macrovascular complications was identified as a risk factor of early COVID-19 severity in inpatients with T1D. Importantly, the severity of COVID-19 appeared less marked in patients with T1D than in those with T2D, with half the risk of death on D7. This lower severity is prominent in the younger group, mostly due to a reduced rate of tracheal intubation. Obesity, more frequent in patients with T2D (55.1% vs. 34.8% for T1D in subjects <55 years), might explain this poorer prognosis, but this will deserve further studies.

While our paper was under review, a National Health Service (NHS) population cohort study including 61,414,470 individuals in England showed that people with T1D ($n = 263,830$; 0.4%) exhibited an increased risk of in-hospital death due to COVID-19 compared with those without known diabetes (OR 3.50 [95% CI 3.15–3.89], after adjustment for age, sex, deprivation, ethnicity, and geographical region). The apparent discrepancy regarding the severity of COVID-19 between the two studies could be explained by some differences in anthropometric characteristics of people with T1D between the two countries (i.e., patients with T1D have a lower BMI in France compared with England) but also by differences in study design (medico-administrative vs. investigator-checked data). In accordance with the strong impact of the age on the severity of COVID-19 in T1D, the NHS study reported no deaths in patients younger than 50 years ($n = 142,440$) (6).

Our study displays some limitations. Only inpatients were recruited, and the results cannot be generalized to people with T1D and less severe forms of COVID-19. In addition, we did not

directly compare patients with T1D with matched subjects without diabetes. The size of our study population is limited, and the results should be replicated in other larger studies and/or meta-analyses.

In conclusion, among patients with diabetes requiring hospitalization for COVID-19, the present data suggest a lower risk of severe prognosis in those with T1D, especially in the younger ones.

Acknowledgments. The authors thank Sandrine Fosse-Edorh from Santé Publique France, Saint-Maurice, France, who shared her precious insights regarding the results of the ENTRED study. The authors also thank the sponsor (Délégation à la Recherche Clinique et à l'Innovation, CHU Nantes), the Clinical Project Manager (M. Saignes) and assistant (J. Saunier), Clinical Research Associates (S. El Andaloussi, J. Martin-Gauthier, E. Rebouilleau), and data managers (B. Guyomarc'h, T. Roman). They are grateful to P. Tucker (Trets, France) for editing the manuscript. The authors acknowledge all medical staff involved in the diagnosis and treatment of patients with COVID-19 in participating centers and thank all of the general practitioners, specialists, pharmacists, and biological laboratories responsible for hospitalized patients for providing additional medical information to investigators. The authors thank the Société Francophone du Diabète (SFD) and Société Française d'Endocrinologie for disseminating the study design and organization and the Fédération Française des Diabétiques (FFD) for participating in the organization of the study.

Funding. This study received the following funding: Fondation Francophone de Recherche sur le Diabète (FFRD) supported by Novo Nordisk, Merck Sharp & Dohme (MSD), Abbott, Astra-Zeneca, Lilly and FFD—CORONADO initiative emergency grant; SFD—CORONADO initiative emergency grant; Air Liquide Healthcare international CORONADO emergency grant; Programme hospitalier de recherche clinique (PHRC) National COVID-19 Hospitalization and Care Organization Division as part of the Hospital Clinical Research Program (PHRC COVID-19-20-0138). All research facilities are acknowledged for providing research associates and research technicians for clinical investigations pro bono.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Duality of Interest. M.W. reports personal fees from Novo Nordisk. P.G. reports grants or personal fees from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Mundipharma, Novo Nordisk, Sanofi, and Servier. L.L. reports personal fees from Eli Lilly. O.B. reports personal fees from AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi. P.D. reports personal fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. M.P. reports nonfinancial support or personal fees from Amgen, Novo Nordisk, and Sanofi. L.P. reports personal fees or nonfinancial support from Eli Lilly, MSD, Novo Nordisk, and Sanofi. J.-F.G. reports personal fees and nonfinancial support from AstraZeneca, Gilead, Eli Lilly, and Novo Nordisk. S.H. reports grants, nonfinancial support, or personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Dinno Santé, Eli Lilly, LVL, MSD, Novartis, Pierre Fabre Santé, Sanofi, Servier, and Valbionis. B.C. reports grants, nonfinancial support, or personal fees from Abbott, Amgen, Akcea, AstraZeneca, Pierre Fabre, Genfit, Gilead, Eli Lilly, MSD, Novo Nordisk, Regeneron, and Sanofi. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. M.W., P.G., S.H., and B.C. designed the study. P.G., L.L., D.S.-B., O.B., P.D., C.A., M.P., L.P., C.T., J-F.G., S.H., and B.C. participated in patient recruitment. M.W. performed the statistical analyses. M.W., P.G., M.P., S.H., and B.C. wrote the first draft of the manuscript. All authors performed a critical revision of the manuscript and significantly contributed to the final version. B.C. and M.W. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Richardson S, Hirsch JS, Narasimhan M, et al.; Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA* 2020; 323:2052–2059
2. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *J Clin Virol* 2020;127:104354

3. Cariou B, Hadjadj S, Wargny M, et al.; CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. *Diabetologia* 2020;63:1500–1515
4. Lecomte P, Romon I, Fosse S, Simon D, Fagot-Campagna A. Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001. *Diabetes Metab* 2008;34:219–226
5. Santé Publique France. Échantillon national témoin représentatif des personnes diabétiques, Entred 2007-2010. Caractéristiques, état de santé, prise en charge et poids économique des personnes diabétiques. Saint-Maurice: Institut de veille sanitaire. 2013, 140 pp. Accessed 13 May 2020. Available from <https://www.santepubliquefrance.fr/maladies-et-traumatismes/diabete/documents/rapport-synthese/etude-entred-2007-2010>
6. Barron E, Bakhai C, Kar P, et al. Association of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol*. 13 August 2020 [Epub ahead of print]. DOI: 10.1016/S2213-8587(20)30272-2